United Laboratories International Holdings Dirección

Dirección controles de criterios 1/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	no data
Participación del CEO	n/a
Permanencia media de la dirección	sin datos
Promedio de permanencia en la Junta Directiva	13.5yrs

Actualizaciones recientes de la dirección

Recent updates

CEO

United Laboratories International Holdings no tiene CEO, o no tenemos datos al respecto.

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Hoi Shan Tsoi	Executive Chairman	15.1yrs	CN¥4.00m	0.90% CN¥ 20.2m
Wing Hon Leung	Vice Chairman	17.5yrs	CN¥3.98m	0.0012% CN¥ 27.2k
Su Yan Zhu	VP & Executive Director	13.5yrs	CN¥2.43m	0.000010% CN¥ 225.0
Xian Hong Zou	VP & Executive Director	13.5yrs	CN¥2.43m	0.011% CN¥ 247.7k
Siu Chit Choy	Global Director of Intermediate & Bulk Medicine and Executive Director	10.9yrs	CN¥2.66m	0.0065% CN¥ 146.0k
Yu Ping Fang	VP & Executive Director	13.5yrs	CN¥2.47m	sin datos
Ming Song	Independent Non-Executive Director	17yrs	CN¥222.00k	sin datos
Peng Oon Chong	Independent Non-Executive Director	15.2yrs	CN¥222.00k	sin datos
Qiushi Fu	Independent Non-Executive Director	less than a year	sin datos	sin datos

13.5yrs

Permanencia media

58yo

Promedio de edad

Junta con experiencia: Los miembros de la junta directiva de UNJ son experimentados ( 13.4 años antigüedad media).

United Laboratories International Holdings Dirección

Dirección controles de criterios 1/4

Información clave

Actualizaciones recientes de la dirección

the United Laboratories International Holdings Limited Announces Appointment of Dr. Fu Qiushi as Independent Non-Executive Director and A Member of the Audit Committee, the Remuneration Committee and the Nomination Committee

Less than half of directors are independent

Less than half of directors are independent

Recent updates

New major risk - Revenue and earnings growth

Full year 2023 earnings released: EPS: CN¥1.49 (vs CN¥0.87 in FY 2022)

Investor sentiment improves as stock rises 19%

The United Laboratories International Holdings Limited to Report Fiscal Year 2023 Results on Mar 26, 2024

New minor risk - Share price stability

First half 2023 earnings released: EPS: CN¥0.71 (vs CN¥0.34 in 1H 2022)

The United Laboratories International Holdings Limited Announces FDA Approval of IND for UBT251 Injection

the United Laboratories International Holdings Limited Announces Interim Dividend for Six Months Ended 30 June 2023, Payable on 11 October 2023

The United Laboratories International Holdings Limited Announces Application for the Clinical Trial of Class 1 Innovative New Drug UBT251 Injection

First half 2023 earnings released: EPS: CN¥0.71 (vs CN¥0.34 in 1H 2022)

the United Laboratories International Holdings Limited Announces Ordinary Interim (Semi-Annual) Dividend for Six Months Ended 30 June 2023

New major risk - Revenue and earnings growth

The United Laboratories International Holdings Limited to Report First Half, 2023 Results on Aug 29, 2023

the United Laboratories International Holdings Limited Announces Appointment of Dr. Fu Qiushi as Independent Non-Executive Director and A Member of the Audit Committee, the Remuneration Committee and the Nomination Committee

The United Laboratories International Holdings Limited Approves Special Dividend for the Year Ended 31 December 2022

Full year 2022 earnings released: EPS: CN¥0.87 (vs CN¥0.54 in FY 2021)

Now 20% undervalued

Less than half of directors are independent

The United Laboratories International Holdings Limited Announces Approval of Marketing of Sodium Hyaluronate Eye Drops Applied by Zhuhai United Laboratories Co., Ltd

The United Laboratories International Holdings Limited (SEHK:3933) commences an Equity Buyback Plan for 181,757,450 shares, representing 10% of its issued share capital, under the authorization approved on June 21, 2022.

The United Laboratories International Holdings Limited Announces an Interim Dividend for the Year 2022, Payable on 6 October 2022

First half 2022 earnings released: EPS: CN¥0.35 (vs CN¥0.34 in 1H 2021)

The United Laboratories International Holdings Limited Announces Interim Dividend for the Six Months Ended 30 June 2022

The United Laboratories International Holdings Limited Approves Special Dividend for the Year Ended 31 December 2021, Payable on 20 July 2022

The United Laboratories International Holdings Limited Approves Final Dividend for the Year Ended 31 December 2021

Full year 2021 earnings released: EPS: CN¥0.54 (vs CN¥0.40 in FY 2020)

Less than half of directors are independent

The United Laboratories International Holdings Limited (SEHK:3933) commences an Equity Buyback Plan for 184,039,050 shares, representing 10% of its issued share capital, under the authorization approved on June 22, 2021.

First half 2021 earnings released: EPS CN¥0.34 (vs CN¥0.12 in 1H 2020)

First half 2021 earnings released: EPS CN¥0.34 (vs CN¥0.12 in 1H 2020)

The United Laboratories International Holdings Limited Announces Updated Information of the Group's Products

Full year 2020 earnings released: EPS CN¥0.40 (vs CN¥0.39 in FY 2019)

Full year 2020 earnings released: EPS CN¥0.40 (vs CN¥0.39 in FY 2019)

The United Laboratories International Holdings Limited to Report Fiscal Year 2020 Results on Mar 30, 2021

New 90-day low: €0.52

New 90-day low: €0.58

New 90-day low: €0.67

New 90-day low: €0.71

First half earnings released

New 90-day high - €0.99

First half earnings released

The United Laboratories International Holdings Limited to Report First Half, 2020 Results on Aug 25, 2020

New 90-day low - €0.71

CEO

Miembros de la Junta

Permanencia media

Promedio de edad